在肺高血压中解读内皮甲基化脱酶2,氧化应激和介质素-6相互作用:对精密医学的影响
Yen-Hung Chou1, Yi-Nan Lee2, Shu-Hao Wu3
1Institute of Biomedical Sciences, College of Medicine, MacKay Medical University, New Taipei, Taiwan.
Biochemical pharmacology
|November 2, 2025
概括
内皮甲基脱酶2 (ALDH2) 功能障碍会损害血管功能,并通过增加氧化应激和炎症来促进肺高血压 (PH). ALDH2激活剂对PH治疗有前途,特别是在ALDH2缺乏症患者中.
科学领域:
- 心血管生物学 心血管生物学
- 线粒体医学 线粒体医学
- 肺高血压研究 肺高血压研究
背景情况:
- 线粒体化物脱酶2 (ALDH2) 与肺高血压 (PH) 病原发生有关.
- 之前的研究集中在光滑肌肉细胞上,使内皮功能障碍和氧化应激相互作用不清楚.
研究的目的:
- 研究内皮ALDH2功能障碍,氧化应激和PH进展之间的相互作用.
- 确定内皮ALDH2在肺动脉重塑中的作用.
主要方法:
- 评估了4-hydroxynonenal (4-HNE) 对肺动脉内皮细胞 (PAEC) 血管功能的影响.
- 研究了ALDH2抑制和激活通过p38/NF-κB信号传导对细胞因子分泌的影响.
- 利用PH动物模型来评估ALDH2缺乏和用ALDH2激活剂 (AD-9308) 进行治疗.
- 分析了ALDH2突变的PH患者的临床数据.
主要成果:
- 内皮ALDH2功能障碍和4-HNE积累损害了PAEC血管生成,并促进了促炎性细胞因子分泌 (IL-6,IL-8,FGF2).
- 抑制ALDH2增强了4-HNE诱导的细胞因子释放,推动了肺动脉光滑肌细胞 (PASMC) 的增殖.
- 在PH模型中,ALDH2缺乏增加了肺压力和内皮炎症,ALDH2激活剂AD-9308减轻了这些影响.
- 患有ALDH2突变的PH患者表现出较高的IL-6水平和右心房压力,与较差的结果相关.
结论:
- 内皮ALDH2功能障碍和4-HNE积累有助于通过p38/NF-κB/IL-6通路在PH中的肺动脉重塑.
- ALDH2激活剂代表了PH的潜在精准医学策略,特别是在ALDH2缺乏的人群中.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
557
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
557
Hypertension II: Pathophysiology
770
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
770
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
578
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
578


